Metronidazol/Espiramicina Farmalider

Spiramycin, the active ingredient in Metronidazol/Espiramicina Farmalider, is a macrolide antibiotic combined with Metronidazole, a nitroimidazole, presented for oral administration. The combination treats bacterial infections responsive to macrolides, anaerobic infections, and provides prophylaxis against toxoplasmosis in susceptible individuals and is often prescribed by infectious disease specialists.

GNH USA supplies Metronidazol/Espiramicina Farmalider as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing reliable product quality, regulatory compliance, and timely delivery to meet local and regional health system demands.

Metronidazol/Espiramicina is used to treat bacterial and protozoal infections where both macrolide and nitroimidazole activity are required.

- Bacterial infections susceptible to macrolides: Effective against Gram‑positive and atypical bacteria resistant to other classes. - Anaerobic infections: Targets obligate anaerobes such as Bacteroides and Clostridium species. - Toxoplasmosis prophylaxis: Prevents congenital transmission in pregnant women and infection in immunocompromised patients.

Metronidazol/Espiramicina may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools that may be watery. - Metallic taste: transient metallic sensation in the mouth. - Headache: mild headache. - Vomiting: occasional episodes of vomiting.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Seizures: rare neurologic events, especially with high doses. - Liver toxicity: elevated liver enzymes or jaundice. - Neutropenia: low white blood cell count. - Pseudomembranous colitis: severe colitis due to Clostridioides difficile infection.

Before prescribing Metronidazol/Espiramicina, clinicians should consider several safety precautions.

- Assess allergy history: verify no known hypersensitivity to macrolides or nitroimidazoles. - Monitor liver function: check baseline enzymes and repeat during therapy. - Evaluate renal function: adjust dose in severe impairment if needed. - Avoid alcohol: concurrent intake may cause disulfiram‑like reactions. - Pregnancy and lactation: use only if benefits outweigh risks after professional assessment. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Metronidazol/Espiramicina can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Disulfiram: may cause severe flushing and hypotension. - Warfarin: increased anticoagulant effect, risk of bleeding. - Cyclosporine: elevated levels leading to nephrotoxicity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: reduced effectiveness, advise backup method. - Phenytoin: altered metabolism, monitor seizure control. - Lithium: increased lithium levels, monitor for toxicity.